➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Johnson and Johnson
Baxter
Dow
Boehringer Ingelheim

Last Updated: December 2, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,178,563

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,178,563 protect, and when does it expire?

Patent 8,178,563 protects ODOMZO and is included in one NDA.

This patent has sixty-five patent family members in forty-five countries.

Summary for Patent: 8,178,563
Title:Compounds and compositions as hedgehog pathway modulators
Abstract: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
Inventor(s): Gao; Wenqi (San Diego, CA), Jiang; Jiqing (San Diego, CA), Wan; Yongqin (Irvine, CA), Cheng; Dai (San Diego, CA), Han; Dong (San Diego, CA), Wu; Xu (San Diego, CA), Pan; Shifeng (San Diego, CA)
Assignee: IRM LLC (Hamilton, BM)
Application Number:12/299,290
Patent Claim Types:
see list of patent claims
Compound; Use;

Recent additions to Drugs Protected by US Patent 8,178,563

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Sun Pharma Global ODOMZO sonidegib phosphate CAPSULE 205266 Jul 24, 2015 RX Yes   Start Trial Y   Start Trial U-1722 TREATMENT OF BASAL CELL CARCINOMA
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,178,563

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharma Global ODOMZO sonidegib phosphate CAPSULE;ORAL 205266-001 Jul 24, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,178,563

PCT Information
PCT FiledMay 04, 2007PCT Application Number:PCT/US2007/068292
PCT Publication Date:November 15, 2007PCT Publication Number: WO2007/131201

International Family Members for US Patent 8,178,563

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 060858   Start Trial
Argentina 109423   Start Trial
Australia 2007247860   Start Trial
Brazil PI0711333   Start Trial
Canada 2650248   Start Trial
Chile 2007001269   Start Trial
China 101437800   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Moodys
Harvard Business School
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.